Use of proliferation cell nuclear antigen immunoreactivity for distinguishing hydropic abortions from partial hydatidiform moles

U R Suresh, R J Hale, H Fox, C H Buckley

Abstract

Aims: To determine whether the expression of proliferating cell nuclear antigen (PCNA) in villous cytotrophoblast could distinguish between placental tissue from a hydropic abortion and that from a partial hydatidiform mole.

Methods: Tissue from 18 partial hydatidiform moles, 15 hydropic abortions, five normal first trimester placentas and five normal full term placentas were immunostained for expression of PCNA, using the monoclonal antibody PC10.

Results: PCNA immunoreactivity was very much higher in the cytotrophoblast of normal first trimester placentas than in normal term placentas. Villous tissue from partial hydatidiform moles showed, on average, less immunoreactivity for PCNA than did villous tissue from hydropic abortions.

Conclusions: Immunostaining for PCNA is of no value for differentiating between partial hydatidiform moles and hydropic abortions. The findings indicate that trophoblastic proliferation or hyperplasia is not a feature of partial hydatidiform moles.

In the routine histological examination of placental tissue from abortions it can be very difficult to distinguish between a hydropic abortion and a partial hydatidiform mole, a problem which is largely responsible for the very high level of interobserver variation in the diagnosis of partial moles. This is despite the fact that standard descriptions of the histological features of these two entities seem to indicate sharp differences between them, particular emphasis being laid on the presence of trophoblastic hyperplasia or proliferation as a defining feature of a molar pregnancy. The distinction between a hydropic abortion and a partial mole has practical importance because women diagnosed as having a partial mole are entered into the follow up programme for patients with gestational trophoblastic disease while those thought to have a hydropic abortion are not.

Proliferating cell nuclear antigen (PCNA) is a highly conserved 36 kilodalton acidic nuclear protein, an auxiliary protein of DNA polymerase delta, and is expressed during the late G1 and S phases of the cell cycle. Nuclear PCNA immunoreactivity can be demonstrated in proliferating cells using the monoclonal antibody PC10 and such immunoreactivity is thought to be a marker for cell proliferation.

As villous trophoblastic proliferation or hyperplasia is regarded as a defining feature of a molar gestation, while the villous trophoblast in a hydropic abortion is usually considered to be relatively or absolutely quiescent, demonstration of PCNA expression could serve as an objective means of distinguishing between these two entities.

Methods

Material from 18 partial hydatidiform moles and 15 hydropic abortions was retrieved from the files of the Department of Reproductive Pathology, St Mary's Hospital, Manchester. All the cases had been diagnosed between 1985 and 1988, and each case had been reviewed and the diagnosis confirmed by one of the authors (HF). A diagnosis of partial hydatidiform mole was based on the presence of scattered vesicular villi, often showing central cavitation and very irregular outlines, set in a villous population of normal diameter: in all cases there was some degree of what is conventionally regarded as trophoblastic hyperplasia, though the trophoblast usually showed an atypical pattern, rather than an unusual degree of growth. Sections of placental tissue were also selected from five first trimester terminations of pregnancy carried out for social reasons and from five placentas from uncomplicated full term pregnancies which had resulted in the birth of live infants of normal weight.

Tissue from all cases had been formalin fixed and paraffin wax embedded: the length of fixation was the same in all groups. Sections were cut at 4 μm, dewaxed, and immunostained with the monoclonal antibody PC10 (Novocastra Laboratories: NCL-PCNA) using a conventional avidin-biotin complex method (ABC complex, Dakopatts, England) with light haematoxylin counterstaining. Tissue from normal human tonsil was used as a positive control and substitution of the primary antibody by phosphate buffered saline was used as a negative control.

All immunostained sections were examined by the same observer (US) using a ×40 objective. One thousand villous cytotrophoblastic cells were assessed in each case. Only cells with strong, unequivocal nuclear staining were scored positive. The results were expressed as a percentage and were analysed statistically using the Minotab program.
Results
The results for each of the four diagnostic categories are shown in the table. The difference in counts between first and third trimester placentas was significant \( (p = 0.0022); \) there was also a significant difference between the counts for normal first trimester placentas and both hydropic abortions and partial moles \( (p = 0.0047). \) The difference in counts between hydropic abortions and partial moles was not significant.

Discussion
The findings in placentas from normal pregnancies were exactly as would have been predicted. Thus in first trimester placentas there was very active growth of the trophoblast with the cytotrophoblastic cells functioning as an active germinative zone: at term, villous trophoblastic growth is much diminished though not, as was previously thought, absent. Our results, in this respect, were similar to those obtained by autoradiography, total organ DNA analysis, flow cytometry and morphometric analysis. In normal trophoblast, therefore, PCNA seems to serve as an excellent index of proliferative activity.

The results obtained in aborted placentas and in trophoblast from partial hydatidiform moles were, however, the precise reverse of those which we would have predicted. Indeed, these results have forced us to reappraise the conventional view of trophoblastic proliferation in molar pregnancies. In hydropic abortions the mean count of cells staining positively for PCNA was lower than that for normal first trimester placentas, though in 50% of such cases the values noted fell within the range obtained for normal first trimester trophoblastic tissue. It has to be borne in mind that after fetal death the trophoblast is still fully viable and continues to function, albeit at a diminished level, as indicated by depressed maternal concentrations of hCG, progesterone, and oestradiol. The findings in the trophoblast of hydropic abortions were, therefore, not entirely unexpected, though the apparent degree of proliferative activity was, nevertheless, much greater than would have been expected from the apparently quiescent appearance of the villous trophoblast on light microscopic examination. This may, however, be a reflection of the fact that PCNA staining tends to overestimate the degree of proliferative activity in a tissue due to retention of staining in post-mitotic cells.

In partial hydatidiform moles the percentage of villous cytotrophoblastic cells staining positively for PCNA was, on average, lower than that in placentas from hydropic abortions. This indicates that undue trophoblastic proliferation—hyperlasi—is not a feature of partial hydatidiform moles and indeed any critical review of the histology of partial moles would confirm that this is so in most, though admittedly not all, partial moles. Most partial moles show, in fact, very little trophoblastic proliferation and in most the degree of such proliferation is lower than in normal first trimester placentas. It is the pattern, rather than the degree of trophoblastic proliferation, which is abnormal in partial moles, the villous trophoblast showing focal, multifocal, or circumferential proliferation rather than the polar or lateral proliferation seen in the normal placenta.

It could be argued, when considering these results, that fetal death occurs earlier in pregnancy in hydropic abortions than in partial hydatidiform moles and that therefore these two groups are not strictly comparable. This may be true but further supports our view that trophoblastic proliferation is not a feature of partial moles. If fetal death had occurred at a later stage of gestation in a non-molar abortion, the proliferative activity in the trophoblast in the abortion material would probably have been higher and would further exceed that seen in partial moles. It could further be argued that sampling error may have led to the missing of foci of trophoblastic hyperplasia in the partial hydatidiform moles. There is no reason to believe, however, that the sampling error in placental tissue from partial moles was any greater than in that from surgically terminated pregnancies or from hydropic abortions. Furthermore, if trophoblastic hyperplasia was so focal in partial moles that its presence could be missed as a result of sampling error in all the cases examined it could hardly be argued that hyperplasia of the trophoblast is a defining feature of a mole. Therefore, neither of these arguments detract from the finding that the degree of trophoblastic proliferation in partial hydatidiform moles is less than that in both normal first trimester placentas and in placental tissue from hydropic abortions.

Staining of villous cytotrophoblastic cells for PCNA indicates clearly that trophoblastic hyperplasia is not, despite statements to the contrary, a feature of partial hydatidiform moles. This result is in accord with our suggestion that the trophoblast of partial moles is similar to that of first trimester placentas but continues to increase in size in the later stages of pregnancy.

Use of proliferation cell nuclear antigen immunoreactivity for distinguishing hydropic abortions from partial hydatidiform moles.
U R Suresh, R J Hale, H Fox and C H Buckley

doi: 10.1136/jcp.46.1.48

Updated information and services can be found at:
http://jcp.bmj.com/content/46/1/48

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/